Theophylline for pseudohypoparathyroidism after prior study
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism clinical trials.
This Phase 2 trial tests whether the medicine theophylline can help people with pseudohypoparathyroidism. You may be eligible only if you already completed a specific earlier randomized Phase 2 study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You successfully finished the earlier Phase 2 theophylline study for pseudohypoparathyroidism (IND 133103)
- You do not have a seizure disorder that is not caused by low calcium
- You do not have a history of abnormal heart rhythms (excluding slow heart rate)
- You do not have serious liver problems (like cirrhosis or active hepatitis)
- You are not currently pregnant and do not plan pregnancy in the next year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that follows people who have or may develop parathyroid-related conditions. The goal is to better understand how these problems change over time and what patterns show up, which can help improve future care.
This study is a registry that collects health information from people with chronic low parathyroid hormone (hypoparathyroidism) or pseudohypoparathyroidism. It aims to better understand these conditions and improve future care. You may join if you are an adult living in Germany.
This Phase 4 study tests whether the medicine theophylline can help people with pseudohypoparathyroidism type 1A or 1B. It may be considered if you’re trying to improve how your body uses parathyroid hormone and manage related calcium levels.
This trial tests a new treatment to help people with hypoparathyroidism (a condition where your body doesn't make enough parathyroid hormone, causing low calcium levels) manage their calcium better. It aims to reduce the need for calcium and vitamin D supplements.
This study follows adults with hypoparathyroidism to better understand what symptoms and lab levels change over time. It may help doctors plan future treatments by learning the natural course of the condition, even if you already take standard medicines.
This trial is for adults with hypoparathyroidism who are already taking a drug called palopegteriparatide (TransCon PTH) at a certain dose. It tests whether higher doses of this drug can better control calcium levels and reduce the need for other supplements.
Hear when a new Pseudohypoparathyroidism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.